RxDoctor Payments DataLook up a doctor →

Robin Dalal, MD

Gastroenterology · Nashville, TNNPI 1891011896

Payments from drug & device makers

$847,173in general payments, 2019–2025

Across 422 payments — averaging $2007.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$276K
  • Takeda Pharmaceuticals U.S.A., Inc.$249K
  • Genentech, Inc.$189K
  • Roche Products Limited$128K
  • Fresenius Kabi USA, LLC$2K
  • Janssen Scientific Affairs, LLC$2K
  • plus $750 from 4 others

What the payments were for

  • Consulting fees$21,96880%
  • Travel & lodging$2,4509%
  • Food & beverage$2,91211%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$847,173 in reported general payments places this provider in the 95th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$30,804
Medicare patients
148
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab94$2,481,447
Skyrizi On-BodyRisankizumab-Rzaa50$960,007
RinvoqUpadacitinib37$286,823
Humira(Cf) PenAdalimumab25$270,748
EntyvioVedolizumab21$184,554
XeljanzTofacitinib Citrate33$182,365
Humira(Cf)Adalimumab13$180,898
Budesonide ErBudesonide11$17,034
Mesalamine14$6,337
Mesalamine ErMesalamine18$5,788
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl77$1,083
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine22$660
Ondansetron OdtOndansetron18$647
Omeprazole29$550
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl35$480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$474$2,481,44794 claims
AbbVieRinvoq, Humira(Cf)$276,191$467,72050 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$248,998$184,55421 claims
PfizerXeljanz$131$182,36533 claims
Fresenius Kabi USA, LLCSodium Chloride$2,440$2611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →